Adults w/ insufficiently controlled type 2 DM as an adjunct to diet & exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes. Reduce the risk of major adverse CV events (CV death, non-fatal MI or non-fatal stroke) in adults w/ type 2 DM & established CV disease.
SC Initially 0.25 mg once wkly, increased to 0.5 mg once wkly after 4 wk. After at least 4 wk w/ 0.5 mg once wkly, can be increased to 1 mg once wkly to further improve glycaemic control.
Not to be administered IV or IM. Not to be used in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients w/ CHF NYHA class IV; end-stage renal disease. Consider GI adverse reactions in patients w/ impaired renal function. History of pancreatitis; discontinue if pancreatitis is suspected or confirmed. Increased risk of hypoglycaemia when combined w/ sulfonylurea or insulin. Closely monitor patients w/ diabetic retinopathy treated w/ insulin. Women of childbearing potential are recommended to use contraception while on treatment. Not to be used during pregnancy (discontinue at least 2 mth before planned pregnancy) & lactation. Childn & adolescents <18 yr. Elderly ≥75 yr.
Increased risk of hypoglycaemia w/ sulfonylurea or insulin. Potential to impact the rate of absorption of oral medicinal products that requires rapid GI absorption.
Sign Out
